0.50 / AMA PRA Category 1 Credit(s)TM 0.50 / CNE Contact Hours
This educational activity is jointly provided by the Society of Urologic Nurses and Associates (SUNA) and Haymarket Medical Education.
Supported by an educational grant from Astellas
Overactive bladder (OAB) is a common condition with an enormous impact on patient quality of life; the condition can affect not only the physical but also the psychological, occupational, and social aspects of daily living. Patients with OAB infrequently seek care, or may wait for several years before doing so. Treatment of OAB is subpar; many individuals who have OAB are not currently receiving appropriate treatment, and those who receive traditional pharmacologic therapy often discontinue it as a result of bothersome side effects. Fortunately, recently approved combination approaches to treating OAB have shown great promise in recent years.
In this virtual roundtable discussion, an international panel of experts will review strategies for ongoing monitoring of individuals being treated for OAB. Reasons for the high level of patient dissatisfaction with traditional treatment approaches will be discussed, as will interventions for mitigating the side effects that have been documented with the use of OAB pharmacotherapies. Data on the safety and efficacy of a combination approach that utilizes mirabegron and solifenacin will be presented, as will the implications of these data for practice. The utility of a shared decision-making approach for improved OAB outcomes will be discussed, and clinical situations that may warrant referral to specialty care will be reviewed.
This activity is designed for an international audience of urologists, ob-gyns and primary care (general medicine, internal medicine, family medicine) MDs, DOs, PAs, NPs and RNs.
Learning Outcome After completing these learning activities, the learner will be able to apply evidence-based strategies to appropriately identify and manage care of patients with OAB.
Counsel patients with OAB about behavioral and pharmacologic interventions
Recognize the signs of OAB and formulate an appropriate differential diagnosis to provide timely evidence-based care
Routinely monitor patients taking pharmacotherapy for OAB and make therapeutic adjustments as necessary
Implement combination therapy for patients with OAB who are refractory to monotherapy
Accredited Provider Disclosure of Conflicts of Interest Statement
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. HME and SUNA implement a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners. The relevant financial relationships of those persons in a position to control the content of this CME/CNE activity will be disclosed prior to the start of the educational activity.
This CME/CNE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CNE activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
Paul Doghramji, MD, FAAFP Medical Director of Health Services Ursinus College Collegeville, PA
Dr. Doghramji has no relevant financial relationships to disclose.
Marcus Drake, MD Professor of Physiological Urology Bristol Urological Institute University of Bristol Bristol, UK
Dr. Drake is on the speakers’ bureau for Asofarma, Astellas, and Ferring Pharmaceuticals.
Roger Dmochowski, MD Professor of Urologic Surgery and Gynecology Vanderbilt University Medical Center Nashville, TN
Dr. Dmochowski receives consuling fees from Avadel Pharmaceuticals, Axonics, BlueWind Medical, GTx, Inc., and Serenity Pharmaceuticals.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
The Society of Urologic Nurses and Associates staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
HME will designate each of these enduring activities for a maximum of 0.50 hour of AMA PRA Category 1 CreditTM.
European physicians can submit and apply the AMA certificate of credit to their European-based CE or continuing professional development (CPD).
CNE Contact Hour(s)
The Society of Urologic Nurses and Associates is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number CEP 5556.
SUNA designates this enduring activity for a maximum of 0.50 contact hours for nurses.
Additional Credit Information
Physician Assistant Continuing Education AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.50 Category 1 Credit for completing this activity.
Nurse Practitioner Continuing Education The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for education activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of HME, SUNA, or Astellas. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation/Instructions
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCMETM within your Profile/CME History, which you can access at any time.